Literature DB >> 17925619

Development and validation of a very brief questionnaire measure of physical activity in adults with coronary heart disease.

Alison Orrell1, Patrick Doherty, Jeremy Miles, Robert Lewin.   

Abstract

BACKGROUND: The aim of this study was to validate the Total Activity Measure, a brief questionnaire, to measure physical activity in an older adult population with heart disease.
METHODS: Two versions of the Total Activity Measure were administered twice, 7 days apart. The Total Activity Measure 1 asked respondents for the frequency and average duration of bouts of physical activity at three different intensity levels per week, whereas the Total Activity Measure 2 asked respondents for the total time spent in activity at each activity level per week. Questionnaire accuracy was studied in 62 men and 15 women aged 47-84 years, by repeatability and comparison of both administrations of the Total Activity Measure 1 and Total Activity Measure 2 with 7-day RT3 accelerometer data.
RESULTS: Seventy-three adults (58 men, 15 women) were used for all statistical analyses. Intraclass correlation coefficients for the Total Activity Measure 1 and Total Activity Measure 2 total activity scores (metabolic equivalent per minute) were r=0.73 (95% confidence intervals, 0.56-0.83) and r=0.82 (95% confidence intervals, 0.71-0.88), respectively. Correlations between the Total Activity Measure 1 and RT3 accelerometer for total activity score (metabolic equivalent per minute) were significant, r=0.26 at time 1 and r=0.27 at time 2 for moderate intensity activities. Correlations between the Total Activity Measure 2 and RT3 accelerometer for total activity score (metabolic equivalent per minute) were also significant, r=0.38 at time 1 and r=0.36 at time 2, r=0.31 at time 2 for strenuous intensity activities and r=0.29 at time 1 and r=0.25 at time 2 for moderate intensity activities. Participants overestimated the amount of physical activity on both questionnaires as compared with the RT3 accelerometer.
CONCLUSIONS: The Total Activity Measure 2 was reasonably accurate in assessing total and moderate intensity activity over a 7-day period and demonstrated good test-retest reliability. The Total Activity Measure 1 was less accurate. The Total Activity Measure 2 is a suitable measure of total or moderate intensity physical activity for surveys and audits in an adult cardiac population.

Entities:  

Mesh:

Year:  2007        PMID: 17925619     DOI: 10.1097/HJR.0b013e3280ecfd56

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  9 in total

1.  Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population.

Authors:  Michael J Bly; Stephan F Taylor; Gregory Dalack; Rodica Pop-Busui; Kyle J Burghardt; Simon J Evans; Melvin I McInnis; Tyler B Grove; Robert D Brook; Sebastian K Zöllner; Vicki L Ellingrod
Journal:  Bipolar Disord       Date:  2013-12-13       Impact factor: 6.744

2.  The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia.

Authors:  S A Lott; P R Burghardt; K J Burghardt; M J Bly; T B Grove; V L Ellingrod
Journal:  Pharmacogenomics J       Date:  2012-03-06       Impact factor: 3.550

3.  Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia.

Authors:  Kristen M Ward; A Zarina Kraal; Stephanie A Flowers; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2017-08-02       Impact factor: 4.705

4.  Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs).

Authors:  Vicki L Ellingrod; Stephan F Taylor; Robert D Brook; Simon J Evans; Sebastian K Zöllner; Tyler B Grove; Kristen M Gardner; Michael J Bly; Rodica Pop-Busui; Gregory Dalack
Journal:  Schizophr Res       Date:  2011-04-19       Impact factor: 4.939

5.  DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences.

Authors:  Kyle J Burghardt; J Richard Pilsner; Michael J Bly; Vicki L Ellingrod
Journal:  Epigenomics       Date:  2012-06       Impact factor: 4.778

6.  A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder.

Authors:  Alan R Prossin; Steven S Zalcman; Simon J Evans; McInnis G McInnis; Vicki L Ellingrod
Journal:  Ther Drug Monit       Date:  2013-04       Impact factor: 3.681

7.  Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia.

Authors:  Kj Burghardt; Tb Grove; Vl Ellingrod
Journal:  J Psychopharmacol       Date:  2013-12-17       Impact factor: 4.153

8.  The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects.

Authors:  Vicki L Ellingrod; Tyler B Grove; Kyle J Burghardt; Stephan F Taylor; Gregory Dalack
Journal:  NPJ Schizophr       Date:  2015-11-11

9.  Changes in patient activation following cardiac rehabilitation using the Active+me digital healthcare platform during the COVID-19 pandemic: a cohort evaluation.

Authors:  Gabbi Frith; Kathryn Carver; Sarah Curry; Alan Darby; Anna Sydes; Stephen Symonds; Katrina Wilson; Gordon McGregor; Kevin Auton; Simon Nichols
Journal:  BMC Health Serv Res       Date:  2021-12-24       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.